Mapping Medications: a foundation for clinical decision support for diabetes Health Federation of Philadelphia February 29, 2016.

Slides:



Advertisements
Similar presentations
Disease State Management The Pharmacist’s Role
Advertisements

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association.
Diabesity Management Colette Walter, NP. Objectives 1. Pharmacologic management and understanding of treatment related to the overweight diabetic patient.
Oral Medications to Treat Type 2 Diabetes
Comparing Medications for Adults With Type 2 Diabetes
Barriers to Diabetes Control Mark E. Molitch, MD.
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Diabetes in People with Heart Failure Chapter 28 Jonathan G. Howlett, John C. MacFadyen.
Criteria for the diagnosis of DM Symptoms of diabetes plus random blood glucose concentration ≥ 200 mg/dl OR FPG ≥ 126 mg/dl OR Two –hour plasma glucose.
Clinical Update in Type 2 Diabetes A Case Discussion Dr. Yancey R. Holmes, MD, FACE Ohio Valley Endocrinology.
PHARMACOLOGICAL THERAPY FOR TYPE 2 DIABETES Reyhane Azizi M.D Assistant Prof. of Endocrinology and Metabolism Shahid Sadoghi University of Medical Sciences.
Guidelines for Diabetes Management September 20, 2012 Margaret Pochay RD CDE.
Query Health Distributed Population Queries Implementation Group Meeting November 1, 2011.
Medication Adherence The following module is designed as a basic overview of medication adherence for providers of healthcare, particularly those in a.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 2 Application of Pharmacology in Nursing Practice.
The Role of DPP-IV Inhibitors in the Management of Type 2 Diabetes
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
DH206: Pharmacology Chapter 21: Diabetes Mellitus Lisa Mayo, RDH, BSDH.
Technology to Assist with Diabetes Care February 4, 2011 Margaret Pochay RD CDE.
Supporting the Rationale for the Use of Dapagliflozin as an Add-on to Poorly Controlled Patients on Saxagliptin and Metformin Zachary Bloomgarden, MD Clinical.
Improving Adherence in Type 2 Diabetes Mellitus ALLISON PETZNICK DO NOMS FAMILY MEDICINE SANDUSKY, OH.
Rationale: A significant finding from the Joint Commission – when multiple medications are ordered to treat the same indication (e.g. Pain, Nausea, Constipation)
PATIENT REGISTRIES: THE VALUE OF ASYNCHRONY (NOT ANARCHY), PART II ROBERT KRAFT, MD FEBRUARY 2014.
Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Insulin Therapy for Type 2 Diabetes Mellitus JAMA.
OVERVIEW AAPA and The France Foundation held 30 live chapter meetings for PAs, NPs, family physicians, and osteopathic physicians. An implementation workshop.
Copyright © 2015 by the American Osteopathic Association.
Diabetes Learning Event 7th October 2016
Objectives Review factors for best therapeutic approach for appropriate pharmacologic choices for diabetes management Review cost implications for.
2012 ADA Clinical Practice Guidelines Therapies for DM- Type 2
Associate Professor Medha Munshi
Medicare Part D Program and Outreach Clinics-2017 University of the Pacific Thomas J. Long School of Pharmacy and Health Sciences.
Medicare Part D Program and Outreach Clinics-2017 University of the Pacific Thomas J. Long School of Pharmacy and Health Sciences.
SGLT2 Inhibitors: What Do the Data Mean for My Patients?
SGLT2 Inhibitors and Their Clinical Impact:
Patient Case Discussions in T2D: What Intensification Plan Is Best?
Updates on Outcomes for Novel T2D Therapies
Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.
Updates Abound.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.
How Effective Is Fixed-Dose Combination Therapy in T2D and Where Does It Fit?
GLP-1 Receptor Agonists: How Early Is Appropriate?
Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm  Timothy Bailey, MD  The American.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Case Study Role of DPP-4 Inhibitors
Early and Intensive T2D Management:
Antihyperglycemic therapy in type 2 diabetes: general recommendations
Insulin Use in Primary Care: Practice Challenges
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Antihyperglycemic therapy in type 2 diabetes: general recommendations (17). Antihyperglycemic therapy in type 2 diabetes: general recommendations (17).
T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus
Use of Combination of Saxagliptin/ Dapagliflozin in Patients With Poorly Controlled Diabetes on Metformin.
RCHC’s Cardiovascular Health Initiative
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Approach to starting and adjusting insulin in type 2 diabetes.
Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement.
Add-On Therapy to Insulin in T1DM Management
Patient Selection for Modern T2D Agents
Trends in the relative contribution of each second-line diabetes medication class, by quarter, as a percent of all second-line prescribing, 2011–2015.
Emerging Combination Injectable Therapy A New Era in Diabetes Care
ADA/EASD general recommendations for type 2 diabetes management (1).
Range of mean changes from baseline in A1C in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor agonists.
Jia Min Liau Accredited Pharmacist/ Credentialled Diabetes Educator
Antihyperglycemic therapy in type 2 diabetes: general recommendations (22). Antihyperglycemic therapy in type 2 diabetes: general recommendations (22).
Inpatient Insulin Management on the Wards
Prevalence of prescribing of different anti-diabetic medications as add-on therapy in patients with type 2 diabetes on metformin. *Other=Sum of prevalence.
Antihyperglycemic therapy in adults with type 2 diabetes
Fig. 1. Antihyperglycemic therapy algorithm for adult patients with type 2 diabetes mellitus (T2DM). The algorithm stratifies the choice of medications.
Presentation transcript:

Mapping Medications: a foundation for clinical decision support for diabetes Health Federation of Philadelphia February 29, 2016

 Why am I doing this?  How do I do this?  Now that I’ve mapped, how do I use it? Today’s Plan

 Building blocks to craft refined searches for diabetes  Support population health management  Outreach efforts  Provider engagement  Clinical decision support  Patient safety tool  Identification of outliers (providers) Why am I doing this?

How? Medication mapping  First, a word about Medication categories – these are a legacy from pre-EHR interface days. Don’t go there.

Medications  Now, check your Medications – are there Medications that represent useful groupings for your practice?

What you might find:

Disable the irrelevant!

Medication classes OralsInsulinsOther DM injectables ThiazolidinedionesLong-actingGLP-1 agonists SGLT2 InhibitorsShort-actingAmylin agonists Bile Acid SequestrantsNPH/fast- acting mixes Meglitinides… Sulfonylureas DPP-4 inhibitors Alpha-glucosidase inhibitors Biguanides

Medication grouping rationale  Identify potentially risky combinations  Distinguish evidence-based practice from not (eg metformin candidates who are not prescribed it)  Identify patients on a given therapy combination without improvement (who would be due for dose or regimen change) … I recommend mapping each class (not each medication) separately

Medication mapping: biguanides

 For a comprehensive list, refer to practice-recommendations, p. S55 (Table 7.1) practice-recommendations Finding all the right meds?

 Identify patients with A1c>6.5, NO metformin, and NO creatinine >=1.5 on most recent measurement. Saved in (Protocols), this search will populate the huddle sheet as “Consider metformin”. For optimal provider satisfaction, build in a metformin intolerance (‘allergy’) filter as well. Now that I’ve mapped, how do I use it?

(Protocols): consider insulin

 Prescribing the right med is only the beginning… but it can help you catch some low-hanging fruit.  Later: need to be able to capture  Adherence  Barriers  Education Is this enough?